MS and Demyelinating Disorders

The professor of neurology at the University of Saskatchewan discussed the need to improve therapeutics aimed at improving neurodegeneration in patients with multiple sclerosis. [WATCH TIME: 3 minutes]

At the end of the open-label extension period, 77.5% of patients reported treatment-emergent adverse events and 27.7% had a treatment-related TEAE.

Investigators utilized a social media listening tool to evaluate and scale mentions of disease-modifying therapy use by women with multiple sclerosis, with the majority of concerns focused on safety and treatment reinitiation in the postpartum period.

Although there were no differences between herpes simplex virus types 1 and 2, patients with MS did show increased levels of EBV capsid antigen and EBNA compared with controls.

Both ozanimod doses were associated with greater median reductions in plasma neurofilament light and mean improvements in SDMT score change than interferon beta-1a at month 12 of treatment.

The professor of neurology at the University of Saskatchewan discussed his presentation at the 2022 CMSC Annual Meeting on using ribonucleoprotein A1 antibodies to drive neurodegeneration in multiple sclerosis. [WATCH TIME: 4 minutes]

Stephen Krieger, MD, of the Icahn School of Medicine and Corinne Goldsmith Dickinson Center for MS at Mount Sinai, shared his perspectives on the trends in multiple sclerosis and the need to holistically treat patients to maximize brain reserve.

Emily Harrington, MD, PhD, physician-scientist at The Ohio State University Wexner Medical Center, provided thoughts on the importance of World MS Day and the issues that plague the MS community.

The professor of neurology at MedStar Georgetown University Hospital shared his perspective on the trends in thinking about the treatment of MS and how an improved understanding of underlying processes has led to a shift in the field. [WATCH TIME: 5 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is World MS Day.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 27, 2022.

David Evans, MBA, shared his experience from this year’s event and spoke about the progress that’s been made in advocating for patients in the last several years at the AAN's Neurology on the Hill conference.

Expert neurologists discuss factors guiding their choice of high-efficacy therapy in multiple sclerosis.

Regina Berkovich, MD, PhD, shares her approach to selecting high-efficacy therapies in clinical practice for patients with multiple sclerosis.

Drs Obeidat and Okai discuss long-term data with oral DMTs that were recently presented at ACTRIMS 2022.

MS experts highlight the value of monitoring and use of risk mitigation strategies when taking care of patients with MS.

Patients with relapsing multiple sclerosis who had progression independent of relapse activity were subject to global brain tissue loss similar to that of patients experiencing solely relapse activity.

June Halper, MSN, APC-C, MSCN, FAAN, the chief executive officer of the Consortium of Multiple Sclerosis Centers, shared her perspective on what to expect from this year’s annual meeting, which takes place June 1-4, 2022, in National Harbor, Maryland.

Although neutropenic fever was common among patients, there was no significant difference between disease-modifying therapies, including those with long-lasting effects.

The assistant professor of neurology at The Ohio State University Wexner Medical Center provided insight on finding strategies to prevent neurodegeneration in multiple sclerosis. [WATCH TIME: 3 minutes]

Here's what is coming soon to NeurologyLive®.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neuropathic disorders.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 20, 2022.

Dr Barry A. Hendin reviews the use of high efficacy therapy in MS.

Regina Berkovich, MD, PhD, defines inflammation in multiple sclerosis and its role in MS pathogenesis.

Dr Okai provides an overview of oral DMTs available to patients with RRMS.

Two MS experts discuss shared decision-making and other considerations in choosing MS treatment.

The importance of addressing disorders of the brain cannot be overstated, and doing so will be essential to our generation and generations to come.

Here's what is coming soon to NeurologyLive®.